Selling a DME Business in 2026: Multiples, Named Buyers, and the Subsegment Playbook

If you operate a DME business in 2026 — whether that is a single-location commodity provider, a regional respiratory/CPAP specialist, or a multi-state complex-rehab platform — the M&A market is active but highly bifurcated by subsegment. AdaptHealth and Lincare are consolidating respiratory and home-medical, Owens & Minor’s $1.6B Apria Healthcare acquisition in 2022 reset the platform-multiple ceiling, ResMed has been moving deeper into direct-to-consumer resupply, and PE-backed platforms (Numotion, National Seating & Mobility, plus tuck-in roll-ups) are aggressive in complex rehab.

What the asset is worth depends on three things: (1) which DME subsegment you are in (respiratory and CPAP is the premium bucket; commodity equipment is the low bucket), (2) the payer mix and in-network commercial / Medicare Advantage contract footprint, and (3) the operational backbone — specifically DMEPOS accreditation, modern operating system (Brightree, Apacheta, FastTrack, NikoHealth), and resupply automation. This guide gives you real multiples ranges by subsegment, the named buyers actually transacting, and the operator-level diligence buyers will run.

Named DME M&A transactions (2022-2025)

The transactions below are public or widely-disclosed deals. They show an active market with named buyers writing big checks:

The named buyer landscape

The most important thing a seller needs to know is who is actually buying DME businesses right now, what they pay for, and what they will reject. The buyer pool falls into four buckets:

Public / strategic buyers

• AdaptHealth (NASDAQ: AHCO, $3B+ revenue) — the largest US respiratory and home-medical-equipment provider, post the AeroCare merger. Active tuck-in acquirer in respiratory and sleep.
• Lincare Holdings (Linde plc subsidiary, $2B+ revenue) — respiratory and oxygen focused, multi-state. Active acquirer of respiratory regional providers.
• Owens & Minor (NYSE: OMI) — acquired Apria Healthcare in 2022 for $1.6B disclosed. Operates Apria and Byram Healthcare (ostomy/urology/wound care).
• ResMed (NYSE: RMD) — manufacturer with direct-to-consumer DME and resupply via Brightree, MEDIFOX DAN, and ResMed-branded supply business.
• Inogen (NASDAQ: INGN) — portable oxygen-focused, vertically integrated.

PE-backed complex-rehab platforms

• Numotion — PE-backed, the largest US complex-rehab DME provider. Active acquirer.
• National Seating & Mobility — PE-backed, complex-rehab specialist. Active acquirer.

PE-backed DME platforms across other subsegments

• BlackRock, Webster Equity Partners, Linden Capital, Court Square Capital, NewSpring Capital, One Equity Partners — multiple PE sponsors with DME or DME-adjacent portfolio companies actively rolling up.

Subsegment-specific specialty buyers

• Byram Healthcare (Owens & Minor subsidiary) — ostomy, urology, wound care, diabetic.
• Edgepark Medical Supplies (Cardinal Health / Independence Holding) — mail-order ostomy and urology.
• Diabetic supply specialists like CCS Medical, ADS, and Solara Medical (CGM and diabetic supplies).

What each buyer will pay for vs. what they reject

• Will pay premium for: respiratory and sleep subsegment exposure, recurring resupply revenue (CPAP, oxygen, ostomy, diabetic), commercial / Medicare Advantage in-network status, modern DME operating system (Brightree, NikoHealth, FastTrack, Apacheta), DMEPOS accreditation cleanliness, multi-state licensure, automated documentation workflows (medical necessity, CMNs, prior auths), patient adherence/compliance management programs.
• Will compress or reject: commodity DME mix above 50%, heavy Medicare competitive-bidding exposure without strategy, legacy operating systems (paper-based or older billing platforms), DMEPOS accreditation findings or open audits, single-payer concentration above 25%, single-referrer concentration, RAC/UPIC audit history without clean resolution.

The operator-level KPI playbook buyers will diligence

Subsegment mix and revenue composition

• Revenue mix by subsegment: Respiratory + sleep %, complex rehab %, ostomy/urology %, diabetic %, commodity %. The mix drives the multiple.
• Recurring resupply revenue: CPAP, oxygen, ostomy, diabetic resupply percentage of revenue. 50%+ recurring resupply is the premium-multiple benchmark for respiratory/sleep platforms.
• Capital sale vs. capped rental revenue: Track Medicare-capped rental and capped-rental conversion dynamics carefully.

Payer mix

• Medicare FFS vs. Medicare Advantage: MA growth is structurally favorable for DME; pure Medicare FFS exposure without MA contracts compresses.
• Commercial percentage: 40%+ commercial is a multiple-builder.
• Medicare competitive bidding (CBA): Document contract position in your competitive-bidding areas; non-contract suppliers in CBAs face structural disadvantages.
• Single-payer concentration: No single payer over 25% of revenue.

Referral source and patient acquisition

• Referral source mix: Hospital systems, sleep labs, physician practices, home health agencies, direct-to-consumer.
• Single-referrer concentration: No referrer over 20% of revenue.
• Direct-to-consumer / digital acquisition: DTC patient acquisition is a real multiple-builder for resupply-heavy subsegments.
• Patient adherence/compliance programs: CPAP adherence at 90 days, oxygen reorder frequency, ostomy reorder timeliness.

Operations and technology stack

• DME operating system: Brightree (ResMed) is the dominant platform; NikoHealth, FastTrack, Apacheta, TeamDME also common. Legacy or home-grown systems trigger integration discounts.
• Documentation automation: Medical necessity / CMN / prior authorization workflow automation. Days-from-order-to-delivery KPI.
• Resupply automation: Auto-reorder programs, refill rates, patient outreach.
• Fleet and delivery operations: Owned fleet vs. third-party delivery, service-level metrics, geographic coverage.

Accreditation, licensure, and compliance

• DMEPOS accreditation: Current, no findings, on file for every CMS supplier number.
• State DME licensure: Multi-state licensure footprint, all current.
• Audit history: RAC, UPIC, ZPIC, TPE audit history disclosed and resolved.
• Surety bonds and bonds posted: CMS supplier number bonds in good standing.

RCM

• Days in AR: <55 days is healthy for DME (slightly longer than typical healthcare RCM due to documentation cycles).
• Denial rate: <10% first-pass.
• Cash collections: Monthly cash collections vs. expected; aged AR > 120 days disclosure.
• Patient self-pay collections: Documented financial-assistance and patient-payment programs.

Dangers and traps in DME M&A

1. Medicare competitive bidding (CBA) exposure

If your Medicare revenue is concentrated in competitive-bidding areas and you are not a contract supplier, buyers will model in structural reimbursement compression and bidding-cycle risk. Document your CBA contract position and strategy.

2. Commodity DME concentration

If 50%+ of revenue is commodity equipment (walkers, basic mobility, hospital beds), the multiple compresses. Premium multiples require respiratory/sleep, complex rehab, ostomy, or diabetic resupply revenue.

3. Audit history and resolution status

Any open RAC, UPIC, ZPIC, or TPE audit is a real diligence concern. Resolve and document before going to market. CERT error rate disclosure also expected.

4. Documentation and medical-necessity hygiene

DME documentation is a frequent audit trigger. CMN, face-to-face, written orders, medical records — all must be current, on file, and audit-defensible. Internal compliance audit before going to market is cheap insurance.

5. Capped-rental mechanics surprises

Medicare capped-rental dynamics (oxygen, CPAP, mobility) have complex revenue-recognition implications. Make sure your accounting handles them cleanly and Q-of-E doesn’t find a surprise.

6. Sleep lab / DTC marketing referrer compliance

Anti-kickback and Stark exposure around sleep-lab referrals, physician relationships, and DTC marketing partnerships must be reviewed by counsel.

7. Legacy operating system integration discount

If you are on paper-based workflows or a legacy billing system, expect a buyer-side integration project and discount. Modernize before going to market if you can.

8. Patient adherence and resupply churn risk

CPAP non-compliance at 90 days, oxygen reorder lapses, ostomy patient attrition — track and disclose these metrics; buyers model them into terminal-value retention assumptions.

Our POV on DME M&A in 2026

The honest read on the market: DME is a deeply consolidated and highly capitalized M&A space, but the bifurcation by subsegment is real.

• If you are a commodity DME provider, multiples are 3x-6x and buyer pool is small. Focus on operational cleanliness, accreditation, and Medicare CBA strategy. Premium multiples require subsegment diversification into respiratory, complex rehab, or specialty resupply.
• If you are a regional respiratory or sleep DME provider, you are in the sweet spot for AdaptHealth, Lincare, ResMed (resupply), and PE tuck-ins. Multiples 7x-10x. Resupply automation and adherence programs are multiple-builders.
• If you are a complex-rehab DME provider, your buyer pool is Numotion, National Seating & Mobility, and PE-backed specialists. Multiples 6x-10x. Pediatric mobility is a premium niche.
• If you are an ostomy/urology/diabetic specialty DME, your buyer pool includes Byram Healthcare (Owens & Minor), CCS Medical, Edgepark, ADS, Solara Medical, plus PE sponsors. Multiples 5x-9x. CGM and diabetic-supply consolidation has its own dynamics.
• If you are a premium scale platform ($10M+ EBITDA, respiratory/sleep focus, MA/commercial in-network, modern operating system, resupply automation), you are a strategic target. 10x-12x+ is achievable.

The right time to prepare is 12-18 months before going to market — clean up DMEPOS accreditation, document audit history, modernize the operating system, build the management bench, and run a real compliance audit. The buyer pool will pay for quality.

Preparing your DME business for sale: 12-18 months out

1. Get multi-year audited or reviewed financials. Track capped-rental mechanics cleanly in the accounting.
2. Run a compliance and documentation audit. Internal audit of CMN/face-to-face/medical-necessity documentation. Resolve gaps before going to market.
3. Document audit history. RAC, UPIC, ZPIC, TPE, CERT error rate — all disclosed and resolved.
4. Confirm DMEPOS accreditation cleanliness. All supplier numbers, all surveys current.
5. Document Medicare CBA contract position and strategy.
6. Modernize the operating system if needed. Migrate to Brightree, NikoHealth, FastTrack, or another modern platform. Document automation workflows.
7. Build resupply automation. Auto-reorder programs, patient outreach, adherence tracking. This is a multiple-builder for respiratory/sleep, ostomy, and diabetic.
8. Diversify payer and referrer concentration. No single payer or referrer above ~20-25%.
9. Build the management bench. Director of Operations, Compliance Officer, RCM Director should be in place and able to stay through transition.
10. Run a competitive process. The public strategics (AdaptHealth, Lincare, Owens & Minor, ResMed), the complex-rehab specialists (Numotion, NSM), the subsegment specialists (Byram, Edgepark, CCS Medical, Solara), and the PE sponsors are all potential buyers. A real auction with multiple buyers in the room is worth 1-3 turns of EBITDA over a single-bidder negotiation.

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for a DME business in 2026?

Multiples vary by subsegment: respiratory/sleep DME (CPAP, oxygen, ventilation) goes 7x-12x EBITDA, complex rehab and pediatric mobility 6x-10x, ostomy/urology and diabetic supplies 5x-9x, commodity DME (walkers, basic mobility, hospital beds) 3x-6x. Premium scale platforms ($10M+ EBITDA with respiratory focus, modern operating system, in-network commercial / MA contracts) reach 10x-12x+.

Who are the active buyers of DME businesses right now?

Public/strategic: AdaptHealth (NASDAQ: AHCO, $3B+ revenue), Lincare Holdings (Linde plc, $2B+), Owens & Minor (NYSE: OMI, acquired Apria 2022 for $1.6B), ResMed (NYSE: RMD), Inogen (NASDAQ: INGN). PE-backed complex rehab: Numotion, National Seating & Mobility. Subsegment specialists: Byram Healthcare (Owens & Minor), Edgepark, CCS Medical, ADS, Solara Medical. PE sponsors: BlackRock, Webster Equity Partners, Linden Capital, Court Square Capital, NewSpring Capital.

Why does DME subsegment matter so much for multiples?

Respiratory/sleep has structurally high recurring resupply revenue (CPAP supplies, oxygen, ventilation supplies), commercial payer mix, and patient stickiness. Complex rehab has high per-unit revenue and physician-relationship moats. Commodity DME (basic walkers, hospital beds) is highly competitive, low-margin, and subject to Medicare competitive bidding, so multiples are much lower.

What hurts a DME business’s valuation most?

Commodity DME mix above 50%, heavy Medicare competitive-bidding exposure without contract supplier status or a clear strategy, legacy operating systems, DMEPOS accreditation findings or open audits, single-payer concentration above 25%, single-referrer concentration, and an unresolved RAC/UPIC/ZPIC audit history.

What is Medicare competitive bidding (CBA) and why does it matter?

CMS competitive-bidding program awards multi-year supplier contracts for certain DME categories in defined geographic areas. Non-contract suppliers in CBAs face structural reimbursement and access disadvantages. Buyers will scrutinize your CBA contract position and the strategy for areas where you are not a contract supplier.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing as part of their acquisition cost.

How long does it take to sell a DME business?

Once you go to market with a buyer-paid advisor, a typical process runs 5-8 months from initial outreach to closing. Add 12-18 months of preparation work before going to market for the cleanest result (compliance audit, audit-history resolution, operating-system modernization, accreditation cleanliness, management bench).

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. That gives time to clean up DMEPOS accreditation, document and resolve any audit history, modernize the operating system, build resupply automation, diversify payer and referrer concentration, and build the management bench. Starting 3-6 months out leaves significant value on the table.

Related research

• How to sell an infusion therapy business
• How to sell a home health agency
• How to sell a clinical laboratory
• How to sell an urgent care center
• How to sell a physical therapy practice
• How to sell a medical billing company
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Private equity value creation
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch